{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:34:07Z","timestamp":1793057647046,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T00:00:00Z","timestamp":1750550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T00:00:00Z","timestamp":1750550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Dysferlin (DYSF) has a crucial role in sarcolemmal repair. While <jats:italic>DYSF<\/jats:italic> mutations commonly manifest as limb-girdle muscular dystrophy (LGMDR2) or distal Miyoshi myopathy, atypical manifestations, such as asymptomatic hyperCKemia and pseudometabolic myopathy, are rarely reported. We describe clinical, serologic, radiologic, genetic, and muscle pathology findings of three patients with rare dysferlinopathy phenotypes and long-term follow up in one of them. We also review the literature pertinent to uncommon forms of dysferlinopathy presenting with hyperCKemia and pseudometabolic phenotype.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Patient 1 is a 51-year-old female with exercise-induced myalgia predominantly affecting calf muscles for 7\u00a0years. She had a 22-year history of asymptomatic hyperCKemia (CK 812\u20132,223 U\/L). Neurologic exam showed mild calf enlargement without weakness. CT of the lower limb revealed fatty infiltration of distal peroneal and calf muscles. Genetic testing showed two <jats:italic>DYSF<\/jats:italic> variants, c.2163-2A\u2009&gt;\u2009G (pathogenic) and c.866C\u2009&gt;\u2009G, p.Ser289Cys (VUS), unknown if heteroallelic. Muscle biopsy demonstrated nuclei internalization and absent dysferlin immunoreactivity. Patient 2 is a 20-year-old male, football player, with an episode of exercise-induced myalgia followed by asymptomatic persistent hyperCKemia (729\u20132,645 U\/L). He had normal strength but mild calf muscle atrophy. Muscle MRI demonstrated subtle T2 hyperintensity in the posterior leg compartment musculature. He has two heteroallelic <jats:italic>DYSF<\/jats:italic> variants, c.6008G\u2009&gt;\u2009A, p.Gly2003Asp (pathogenic) and c.854C\u2009&gt;\u2009T, p.Thr285Met (VUS). Muscle biopsy showed no myopathic changes but reduced dysferlin immunoreactivity. Patient 3 is a 58-year-old female with incidentally detected asymptomatic hyperCKemia (CK: 249\u20132,096 U\/L) for 2\u00a0years. She had normal strength and normal lower limb muscle MRI. She carries two heteroallelic <jats:italic>DYSF<\/jats:italic> variants, c.2517del, p.Met840Trpfs*108 (pathogenic) and c.6058C\u2009&gt;\u2009T, p.Arg2020Cys (VUS). Muscle biopsy showed minimal myopathic changes and attenuated dysferlin immunoreactivity. Reduced dysferlin expression was confirmed by western blot in patients 2 and 3. Needle EMG was normal in all patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Dysferlinopathy should be considered in the differential diagnosis of metabolic myopathies and asymptomatic hyperCKemia. Patient 1\u2019s long history of hyperCKemia without weakness over two decades suggests that CK elevation in dysferlinopathy does not necessarily predict development of weakness. Additionally, the lack of dystrophic changes on muscle biopsy of patients with asymptomatic or minimally symptomatic hyperCKemia should not discourage the search for dysferlin deficiency in muscle, particularly in the setting of <jats:italic>DYSF<\/jats:italic> variants.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03850-w","type":"journal-article","created":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T20:57:23Z","timestamp":1750625843000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Dysferlinopathy as cause of long-term hyperCKemia with preserved strength"],"prefix":"10.1186","volume":"20","author":[{"given":"Ikreet","family":"Cheema","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teerin","family":"Liewluck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Charles","family":"Bucelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Pestronk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4338-9007","authenticated-orcid":false,"given":"Margherita","family":"Milone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,22]]},"reference":[{"key":"3850_CR1","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nature01573","volume":"423","author":"D Bansal","year":"2003","unstructured":"Bansal D, Miyake K, Vogel SS, et al. Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature. 2003;423:168\u201372.","journal-title":"Nature"},{"key":"3850_CR2","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s00401-002-0654-1","volume":"105","author":"A Prelle","year":"2003","unstructured":"Prelle A, Sciacco M, Tancredi L, et al. Clinical, morphological and immunological evaluation of six patients with dysferlin deficiency. Acta Neuropathol. 2003;105:537\u201342.","journal-title":"Acta Neuropathol"},{"key":"3850_CR3","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1001\/archneur.64.8.1176","volume":"64","author":"K Nguyen","year":"2007","unstructured":"Nguyen K, Bassez G, Krahn M, et al. Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes. Arch Neurol. 2007;64:1176.","journal-title":"Arch Neurol"},{"key":"3850_CR4","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.nmd.2008.01.004","volume":"18","author":"L Klinge","year":"2008","unstructured":"Klinge L, Dean AF, Kress W, et al. Late onset in dysferlinopathy widens the clinical spectrum. Neuromuscul Disord. 2008;18:288\u201390.","journal-title":"Neuromuscul Disord"},{"key":"3850_CR5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2169\/internalmedicine.47.0519","volume":"47","author":"S Okahashi","year":"2008","unstructured":"Okahashi S, Ogawa G, Suzuki M, Ogata K, Nishino I, Kawai M. Asymptomatic sporadic dysferlinopathy presenting with elevation of serum creatine kinase. Typical distribution of muscle involvement shown by MRI but not by CT. Intern Med. 2008;47:305\u20137.","journal-title":"Intern Med."},{"key":"3850_CR6","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1212\/WNL.0b013e3181a1885e","volume":"72","author":"M Fanin","year":"2009","unstructured":"Fanin M, Nascimbeni AC, Aurino S, et al. Frequency of LGMD gene mutations in Italian patients with distinct clinical phenotypes. Neurology. 2009;72:1432\u20135.","journal-title":"Neurology"},{"key":"3850_CR7","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1212\/WNL.0b013e3181ea1564","volume":"75","author":"C Paradas","year":"2010","unstructured":"Paradas C, Llauger J, Diaz-Manera J, et al. Redefining dysferlinopathy phenotypes based on clinical findings and muscle imaging studies. Neurology. 2010;75:316\u201323.","journal-title":"Neurology"},{"key":"3850_CR8","doi-asserted-by":"publisher","first-page":"495","DOI":"10.5692\/clinicalneurol.52.495","volume":"52","author":"Y Kobayashi","year":"2012","unstructured":"Kobayashi Y, Takahashi T, Sumi H, et al. A case of dysferlinopathy asymptomatic for 10 years after an episode of transient muscle weakness. Rinsho Shinkeigaku. 2012;52:495\u20138.","journal-title":"Rinsho Shinkeigaku"},{"key":"3850_CR9","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1177\/0883073812444607","volume":"28","author":"S Moody","year":"2012","unstructured":"Moody S, Mancias P. Dysferlinopathy presenting as rhabdomyolysis and acute renal failure. J Child Neurol. 2012;28:502\u20135.","journal-title":"J Child Neurol"},{"key":"3850_CR10","first-page":"275","volume":"20","author":"F Li","year":"2014","unstructured":"Li F, Yin G, Xie Q, Shi G. Late-onset dysferlinopathy presented as \u201cliver enzyme\u201d abnormalities: a technical note. JCR: J Clin Rheumatol. 2014;20:275\u20137.","journal-title":"JCR: J Clin Rheumatol"},{"key":"3850_CR11","doi-asserted-by":"publisher","first-page":"635","DOI":"10.4103\/0028-3886.149386","volume":"62","author":"J Xi","year":"2014","unstructured":"Xi J, Blandin G, Lu J, et al. Clinical heterogeneity and a high proportion of novel mutations in a Chinese cohort of patients with dysferlinopathy. Neurol India. 2014;62:635.","journal-title":"Neurol India"},{"key":"3850_CR12","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000089","volume":"2","author":"E Harris","year":"2016","unstructured":"Harris E, Bladen CL, Mayhew A, et al. The clinical outcome study for dysferlinopathy: an international multicenter study. Neurol Genet. 2016;2: e89.","journal-title":"Neurol Genet"},{"key":"3850_CR13","first-page":"77","volume":"8","author":"ZR Umakhanova","year":"2017","unstructured":"Umakhanova ZR, Bardakov SN, Mavlikeev MO, et al. Twenty-year clinical progression of dysferlinopathy in patients from Dagestan. Front Neurol. 2017;8:77.","journal-title":"Front Neurol"},{"key":"3850_CR14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12920-022-01284-y","volume":"15","author":"C Contreras-Cubas","year":"2022","unstructured":"Contreras-Cubas C, Barajas-Olmos F, Frayre-Mart\u00ednez MI, et al. Dysferlinopathy misdiagnosed with juvenile polymyositis in the pre-symptomatic stage of hyperCKemia: a case report and literature review. BMC Med Genom. 2022;15:139.","journal-title":"BMC Med Genom"},{"key":"3850_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12846","volume":"48","author":"C Folland","year":"2022","unstructured":"Folland C, Johnsen R, Botero Gomez A, et al. Identification of a novel heterozygous DYSF variant in a large family with a dominantly-inherited dysferlinopathy. Neuropathol Appl Neurobio. 2022;48: e12846.","journal-title":"Neuropathol Appl Neurobio"},{"key":"3850_CR16","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1186\/s12887-022-03561-2","volume":"22","author":"J Katz","year":"2022","unstructured":"Katz J, Labilloy A, Lee A. Recurrent, non-traumatic, non-exertional rhabdomyolysis after immunologic stimuli in a healthy adolescent female: a case report. BMC Pediatr. 2022;22:515.","journal-title":"BMC Pediatr"},{"key":"3850_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10048-022-00707-3","volume":"24","author":"S Nashi","year":"2022","unstructured":"Nashi S, Polavarapu K, Bardhan M, et al. Genotype\u2013phenotype correlation and natural history study of dysferlinopathy: a single-centre experience from India. Neurogenetics. 2022;24:43\u201353.","journal-title":"Neurogenetics."},{"key":"3850_CR18","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1186\/s12883-022-02905-w","volume":"22","author":"N Wang","year":"2022","unstructured":"Wang N, Han X, Hao S, et al. The clinical, myopathological, and molecular characteristics of 26 Chinese patients with dysferlinopathy: a high proportion of misdiagnosis and novel variants. BMC Neurol. 2022;22:398.","journal-title":"BMC Neurol"},{"key":"3850_CR19","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.nmd.2023.08.007","volume":"33","author":"I Belhassen","year":"2023","unstructured":"Belhassen I, Laroussi S, Sakka S, et al. Dysferlinopathy in Tunisia: clinical spectrum, genetic background and prognostic profile. Neuromuscul Disord. 2023;33:718\u201327.","journal-title":"Neuromuscul Disord"},{"key":"3850_CR20","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1177\/22143602241289227","volume":"11","author":"SN Bardakov","year":"2024","unstructured":"Bardakov SN, Deev RV, Tsargush VA, et al. Asymptomatic and oligosymptomatic states of dysferlinopathy. J Neuromuscular Diseases. 2024;11:1283\u201394.","journal-title":"J Neuromuscular Diseases"},{"key":"3850_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2024.105269","volume":"46","author":"L Sanchez-Casado","year":"2025","unstructured":"Sanchez-Casado L, Evangelista T, Nectoux J, Verebi C, et al. Chronic pain as a presenting feature of dysferlinopathy. Neuromuscul Disord. 2025;46: 105269.","journal-title":"Neuromuscul Disord"},{"key":"3850_CR22","doi-asserted-by":"publisher","first-page":"532","DOI":"10.2169\/internalmedicine.41.532","volume":"41","author":"H Ueyama","year":"2002","unstructured":"Ueyama H, Kumamoto T, Horinouchi H, et al. Clinical heterogeneity in dysferlinopathy. Intern Med. 2002;41:532\u20136.","journal-title":"Intern Med"},{"key":"3850_CR23","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1136\/jnnp-2017-317488","volume":"89","author":"J Diaz-Manera","year":"2018","unstructured":"Diaz-Manera J, Fernandez-Torron R, LLauger J, et al. Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials. J Neurol Neurosurg Psychiatry. 2018;89:1071\u201381.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"3850_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.540098","volume":"11","author":"H Zhang","year":"2021","unstructured":"Zhang H, Li Y, Cheng Q, Chen X, Yu Q, Li Z. Abnormal expression of dysferlin in blood monocytes supports primary dysferlinopathy in patients confirmed by genetic analyses. Front Neurol. 2021;11: 540098.","journal-title":"Front Neurol"},{"key":"3850_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029061","volume":"6","author":"E Gallardo","year":"2011","unstructured":"Gallardo E, de Luna N, Diaz-Manera J, et al. Comparison of dysferlin expression in human skeletal muscle with that in monocytes for the diagnosis of dysferlin myopathy. PLoS ONE. 2011;6: e29061.","journal-title":"PLoS ONE"},{"key":"3850_CR26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40478-022-01320-z","volume":"10","author":"N Becker","year":"2022","unstructured":"Becker N, Moore SA, Jones KA. The inflammatory pathology of dysferlinopathy is distinct from calpainopathy, Becker muscular dystrophy, and inflammatory myopathies. Acta Neuropathol Commun. 2022;10:17.","journal-title":"Acta Neuropathol Commun."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03850-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03850-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03850-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T09:02:00Z","timestamp":1750669320000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03850-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,22]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3850"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03850-w","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,22]]},"assertion":[{"value":"20 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Mayo Clinic Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Ikreet Cheema, Dr. Jacob Goodwin, Dr. Teerin Liewluck: Reports no disclosures. Dr. Robert Bucelli: Site PI for trials sponsored by Biogen MA, Ionis, and QurAlis. Paid consultant for Biogen MA. Honorarium from LGMD Masterclass. Advisory Boards for Regeneron and Biogen MA Inc. PI for the Mitchell and Friends Foundation Research Fund. Equity in Neuroquestions.com. Dr. Alan Pestronk: Reports no disclosures. Dr. Margherita Milone: Receives funding for the Muscular Dystrophy Association (MDA Care Center grant 497263).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"317"}}